Drugs / MON002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04805086 | Mar 2021 → Jun 2022 | COVID-19, pulmonary fibrosis | Guy's and St Thomas' NHS Foundation Trust | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MON002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04805086 ↗ |
| Modality | Cell therapy | “cell therapy” NCT04805086 ↗ |
| Route | Intravenous | “prior to intravenous delivery into patients” NCT04805086 ↗ |